Natalizumab for multiple sclerosis: A case in point for the impact of translational neuroimmunology

Afsaneh Shirani, Olaf Stüve

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Advances in translational neuroimmunology over the last two decades have revolutionized the treatment of relapsing forms of multiple sclerosis. A pathological hallmark of multiple sclerosis is the presence of leukocytes in the areas of disease activity in the CNS.Natalizumab inhibits the trafficking of lymphocytes from the blood into the brain and spinal cord by blocking the adhesion molecule a4-integrin. Representing the enormous success of a molecular targeted approach, natalizumab was the first mAb approved for the treatment of relapsing-remitting multiple sclerosis. However, only a few months after its approval, natalizumab was withdrawn from the market because of an unanticipated life threatening adverse effect: progressive multifocal leukoencephalopathy. Natalizumab was later reintroduced with required adherence to a strict monitoring program. In this article, we review the bench-to-bedside journey of natalizumab, along with the lessons learned from postmarketing studies.

Original languageEnglish (US)
Pages (from-to)1381-1386
Number of pages6
JournalJournal of Immunology
Volume198
Issue number4
DOIs
StatePublished - Feb 15 2017

Fingerprint

Multiple Sclerosis
Progressive Multifocal Leukoencephalopathy
Relapsing-Remitting Multiple Sclerosis
Integrins
Spinal Cord
Leukocytes
Natalizumab
Lymphocytes
Brain

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Natalizumab for multiple sclerosis : A case in point for the impact of translational neuroimmunology. / Shirani, Afsaneh; Stüve, Olaf.

In: Journal of Immunology, Vol. 198, No. 4, 15.02.2017, p. 1381-1386.

Research output: Contribution to journalArticle

@article{042958753f2c4469bc40a8d1612fb981,
title = "Natalizumab for multiple sclerosis: A case in point for the impact of translational neuroimmunology",
abstract = "Advances in translational neuroimmunology over the last two decades have revolutionized the treatment of relapsing forms of multiple sclerosis. A pathological hallmark of multiple sclerosis is the presence of leukocytes in the areas of disease activity in the CNS.Natalizumab inhibits the trafficking of lymphocytes from the blood into the brain and spinal cord by blocking the adhesion molecule a4-integrin. Representing the enormous success of a molecular targeted approach, natalizumab was the first mAb approved for the treatment of relapsing-remitting multiple sclerosis. However, only a few months after its approval, natalizumab was withdrawn from the market because of an unanticipated life threatening adverse effect: progressive multifocal leukoencephalopathy. Natalizumab was later reintroduced with required adherence to a strict monitoring program. In this article, we review the bench-to-bedside journey of natalizumab, along with the lessons learned from postmarketing studies.",
author = "Afsaneh Shirani and Olaf St{\"u}ve",
year = "2017",
month = "2",
day = "15",
doi = "10.4049/jimmunol.1601358",
language = "English (US)",
volume = "198",
pages = "1381--1386",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "4",

}

TY - JOUR

T1 - Natalizumab for multiple sclerosis

T2 - A case in point for the impact of translational neuroimmunology

AU - Shirani, Afsaneh

AU - Stüve, Olaf

PY - 2017/2/15

Y1 - 2017/2/15

N2 - Advances in translational neuroimmunology over the last two decades have revolutionized the treatment of relapsing forms of multiple sclerosis. A pathological hallmark of multiple sclerosis is the presence of leukocytes in the areas of disease activity in the CNS.Natalizumab inhibits the trafficking of lymphocytes from the blood into the brain and spinal cord by blocking the adhesion molecule a4-integrin. Representing the enormous success of a molecular targeted approach, natalizumab was the first mAb approved for the treatment of relapsing-remitting multiple sclerosis. However, only a few months after its approval, natalizumab was withdrawn from the market because of an unanticipated life threatening adverse effect: progressive multifocal leukoencephalopathy. Natalizumab was later reintroduced with required adherence to a strict monitoring program. In this article, we review the bench-to-bedside journey of natalizumab, along with the lessons learned from postmarketing studies.

AB - Advances in translational neuroimmunology over the last two decades have revolutionized the treatment of relapsing forms of multiple sclerosis. A pathological hallmark of multiple sclerosis is the presence of leukocytes in the areas of disease activity in the CNS.Natalizumab inhibits the trafficking of lymphocytes from the blood into the brain and spinal cord by blocking the adhesion molecule a4-integrin. Representing the enormous success of a molecular targeted approach, natalizumab was the first mAb approved for the treatment of relapsing-remitting multiple sclerosis. However, only a few months after its approval, natalizumab was withdrawn from the market because of an unanticipated life threatening adverse effect: progressive multifocal leukoencephalopathy. Natalizumab was later reintroduced with required adherence to a strict monitoring program. In this article, we review the bench-to-bedside journey of natalizumab, along with the lessons learned from postmarketing studies.

UR - http://www.scopus.com/inward/record.url?scp=85014597198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014597198&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1601358

DO - 10.4049/jimmunol.1601358

M3 - Article

C2 - 28167648

AN - SCOPUS:85014597198

VL - 198

SP - 1381

EP - 1386

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 4

ER -